We suggest you BOOKMARK this page and visit it often. All content was current as of the date it was published.
In science and in medicine, information is constantly changing. Published content may become out-of-date as new information and data emerge.
There are many important questions that remain unanswered about COVID-19. This is mainly because there is no data to guide us yet.
Answering the Most Common Questions About COVID-19 Booster Doses and Evusheld for Those with CLL/SLL
CLL Society has been receiving multiple questions surrounding Evusheld and the newly recommended second booster dose (fifth dose in total) for all individuals who are immunocompromised. These new recommendations are applicable to everyone with CLL/SLL.
COVID-19 Vaccine Refusal and Fair Allocation of Scarce Medical Resources: Moving CLL/SLL and Other Immunocompromised Patients to the Top Tier
In a pandemic with scarce resources, governments, medical institutions, and healthcare providers have had to make decisions and/or policies about allocating potentially lifesaving therapies among the many outpatients who might benefit from them.
Living with CLL
I was diagnosed in October 2018. My journey led me to a local hematologist, then a CLL specialist in Houston before settling with a CLL specialist in Dallas where I participated in the ECOG trial.
SPECIAL FEATURE: Registration is Live for Celebrating Long Lives
Registration is officially open for our inaugural, virtual Celebrating Long Lives 5K Walk/Run event! Join us on July 23rd to recognize, support, and raise awareness of those who have been touched by a chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) diagnosis.
We encourage everyone who participates to become a fundraiser for the mission of CLL Society and help us raise $10,000 to provide CLL/SLL patients and caregivers the support and education they need to conquer their diagnosis.
Register by June 30th to receive your event t-shirt before event day. We are all in this together; so let’s all do this together!
The Evolving Role of BTKi’s in CLL
Tuesday, June 28th at 10 AM PT / 1 PM ET
The targeted therapy Bruton tyrosine kinase inhibitors (BTKi’s) have come a long way since revolutionizing CLL treatment with the arrival of ibrutinib. Join CLL Society and Dr. Matthew Davids from Dana Farber Cancer Institute to take a deep dive into different BTKi’s, how they work, how they compare to each other and other treatment options, potential side effects, and the future role of these therapies.
If you missed the May 16th CLL Society webinar, Is a Clinical Trial Right for You?, you can watch the replay here.
ASH 2021: Dr. Kerry Rogers on the Addition of Ianalumab (VAY736) to Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL)
Discussion of a new monoclonal antibody, ianalumab (previously known as VAY736), targeting the B-cell activating factor (BAFF) receptor. We refer to the compound as VAY736 for consistency with the interview and abstract for this article.
ASH 2021: Real-World Disease Burden, Costs and Resource Utilization of Hospital-Based Care Among Mantle Cell Lymphoma, Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia: Disparities and Risk Factors
At the American Society of Hematology Annual Meeting and Exposition, ASH 2021, we learned that we are practicing medicine that is more expensive and provides poorer care to many non-white patients.